Neutralizing and non-neutralizing antibody responses in HIV-1 subtype C chronically infected patients with divergent rates of disease progression

Geospatial HIV-1 subtype C gp120 sequence diversity and its predicted impact on broadly neutralizing antibody sensitivity

Abstract Evolving diversity in globally circulating HIV-1 subty

Additional file 1 of Differences in neutralizing antibody sensitivities and envelope characteristics indicate distinct antigenic properties of Nigerian HIV-1 subtype G and CRF02_AG

Supplementary Material 1: Table S1.Panel of 50 subtype G Envs and 18 CRF02_AG Envs from Nigeria. The

Broadly neutralizing antibody VRC34-combo.1 in complex with HIV fusion peptide (residue 512-519)

Neutralizing activity of broadly neutralizing anti-HIV-1 antibodies against primary African isolates

Abstract Novel therapeutic and preventive strategies are needed

Assessment of neutralizing antibody responses after natural SARS-CoV-2 infection and vaccination in Congolese individuals

Abstract Background Assessing immune responses after vaccination is part of the evaluatio

Pre-Treatment Integrase Inhibitor Resistance and Natural Polymorphisms among HIV-1 Subtype C Infected Patients in Ethiopia

Dolutegravir-based antiretroviral therapy (ART) has been scaled up in many developing countries, inc